What is Sight Diagnostics?
Sight Diagnostics operates at the intersection of artificial intelligence and healthcare, offering a groundbreaking platform for blood analysis and the detection of infectious diseases. Their proprietary technology focuses on 'digitizing' blood samples, enabling more accurate and efficient diagnostic processes. This innovative approach positions Sight Diagnostics as a key player in the rapidly evolving field of medical diagnostics, aiming to improve patient outcomes and streamline laboratory workflows.
How much funding has Sight Diagnostics raised?
Sight Diagnostics has raised a total of $145.8M across 5 funding rounds:
Series A
$6M
Series B
$16M
Other Financing Round
$25M
Series C
$27.8M
Series D
$71M
Series A (2014): $6M with participation from Clal Biotechnology Industries, OurCrowd, Emery Capital, and Innovation Endeavors
Series B (2016): $16M led by OurCrowd, GEOC, and New Alliance Capital
Other Financing Round (2018): $25M supported by Innovation Endeavors
Series C (2019): $27.8M featuring Longliv Ventures
Series D (2020): $71M, investors not publicly disclosed
Key Investors in Sight Diagnostics
Longliv Ventures
Longliv Ventures, part of the CK Hutchison Holdings Group, is a strategic investor focused on empowering consumers globally by addressing health and lifestyle challenges. They invest in startups aiming to enhance offerings and penetrate global markets, with a portfolio spanning telemedicine and chronic condition management.
Innovation Endeavors
Innovation Endeavors is an early-stage venture capital firm that invests in visionary founders and transformational technologies. Their investment thesis, the Super Evolution, combines data, computation, and engineering to transform various industries, including life sciences.
OurCrowd
OurCrowd is a global investment platform that enables its members to invest in promising startups. They are known for their active role in funding innovative companies across various sectors, including technology and healthcare.
What's next for Sight Diagnostics?
With a history of substantial capital raises, including Series A, B, C, and D rounds, Sight Diagnostics appears to be in a scaling phase, leveraging its recent major strategic investment to further develop and deploy its AI-driven diagnostic solutions. The company's trajectory suggests a focus on expanding its market reach and enhancing its technological offerings to address critical needs in infectious disease detection and broader blood analysis. Future growth will likely involve strategic partnerships and continued innovation in AI for healthcare.
See full Sight Diagnostics company page
